Citations

Clear

1031 citation(s) found for "Clark, AS".

Abstract P4-07-56: Mayo Clinic Enterprise patterns of growth-factor utilization for sacituzumab govitecan (SG)-induced neutropenia among patients with metastatic triple negative breast cancer
Clark, Kaylee M. , Carroll, Jamie L., Moreno‐Aspitia, Alvaro , Raheem, Farah , Heil, Ashley, Boyer, Beth, Leon‐Ferre, Roberto A. , Taraba, Jodi L. , Clark, Kaylee, Carroll, Jamie M. , Ernst, Brenda , Mara, Kristin C. , Goetz, Matthew P. , Giridhar, Karthik V. , Taraba, Jodi L

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: P4-07-56-P4-07-56

10.1158/1538-7445.sabcs22-p4-07-56 Get It

Abstract Background: SG was approved in 2020 for the treatment of metastatic triple negative breast cancer (TNBC). The most common grade 3/4 adverse event in the ASCENT trial was neutropenia (51.2%) with a 6% incidence of febrile neutropenia. 1 Package insert recommendations do not endorse primary prophylactic growth factor support, rather only initiating if severe neutropenia occurs on treatment.2 Objective: This study retrospectively reviewed the utilization of growth factor support in patients (pts) with metastatic TNBC initiated on SG at each Mayo Clinic Enterprise site. Methods: We performed a multi-center, retrospective review of all pts with TNBC who received SG from January 2021 to December 2021 at Mayo Clinic sites in Minnesota, Florida, Arizona, and its community-based health system network. Data collected included history of neutropenia with previous cycles of SG resulting in a treatment delay, number of cycles, grade of neutropenia and cycle/day of treatment plan when growth factor added. Pts who received only one dose of SG were excluded. The Fisher’s exact test was utilized to compare the difference in the use of primary prophylaxis between sites. Results: 67 pts received at least two doses of SG. Within this cohort, 42 pts (63%) received growth factor support during treatment with SG. Growth factor support was most often added during the first two cycles (59.5%). A total of 12 patients initiated growth factor with no history of delays related to neutropenia and without neutropenia at the time of administration. Eleven of these pts had growth factor support added on Cycle 1 as primary prophylaxis. Primary prophylaxis was most common at Mayo Clinic – Rochester compared to the other sites (Table 1), however there was not a statistically significant difference (p=0.27). There were 26 pts (39%) with a treatment delay due to neutropenia while receiving SG, of which 21 (81%) were managed with the addition of growth factor (13 pegfilgrastim, 8 filgrastim). The median number of cycles for all pts was 5 (range: 1-25). Pts who received growth factor were treated with a median of 5 cycles (range: 1-25) and pts who did not receive growth factor were treated with a median of 4 cycles (range: 1-19) (p=0.10). Conclusions: We observed wide variability in the use of prophylactic growth factor between Mayo Clinic sites with SG. The optimal practice of growth factor use with SG warrants further exploration. References: 1. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529-1541 2. Immunomedics, Inc. Trodelvy (sacituzumab govitecan-hziy) [package insert]. Foster City, CA: Gilead Sciences; 2020. Table 1: Grade of neutropenia for patients receiving SG when growth factor initiated Citation Format: Kaylee Clark, Jamie L. Carroll, Alvaro Moreno-Aspitia, Brenda Ernst, Farah Raheem, Ashley Heil, Beth Boyer, Kristin Mara, Matthew P. Goetz, Roberto A. Leon-Ferre, Karthik V. Giridhar, Jodi Taraba. Mayo Clinic Enterprise patterns of growth-factor utilization for sacituzumab govitecan (SG)-induced neutropenia among patients with metastatic triple negative breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-07-56.
Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Nanda, Rita , Chien, Jo, Stringer-Reasor, Erica , Sanford, Amy, Clark, Amy S. , Albain, Kathy S. , Sanft, Tara B., Williams, Nicole , Arora, Mili, Asare, Smita , Lu, Ruixiao , Pitsouni, Maria, Wilson, Amy , Perlmutter, Jane , Rugo, Hope, Schwab, Richard B. , Veer, Laura van’t, Berry, Donald A. , Investigators, I-SPY, Isaacs, Claudine , Trivedi, Meghna S. , Vaklavas, Christos , Boughey, Judy C. , Wallace, Anne M. , Thomas, Alexandra , Kennedy, Laura Carpin , Kalinsky, Kevin M. , Han, Hyo S , Elias, Anthony , Falkson, Carla I. , Symmans, W. Fraser , Hylton, Nola M. , Yee, Douglas , DeMichele, Angela , Esserman, Laura J.

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: GS5-03-GS5-03

10.1158/1538-7445.sabcs22-gs5-03 Get It

Abstract Background: I-SPY2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes defined by hormone-receptor (HR), HER2, and MammaPrint (MP) status to evaluate novel agents as neoadjuvant therapy for high-risk breast cancer. The primary endpoint is pathologic complete response (pCR). Cemiplimab is an anti-PD-1 inhibitor approved for the treatment of NSCLC and cutaneous basal and squamous cell CA. Lymphocyte activation gene 3 (LAG-3) binds MHC class II leading to inhibition of T-cell proliferation and activation and is often co-expressed with PD-1. REGN3767 is a fully humanized mAb that binds to LAG-3 and blocks inhibitory T-cell signaling. Concurrent blockade of LAG-3 with an anti-PD-1 may enhance efficacy of an anti-PD-1. Methods: Women with tumors ≥ 2.5cm were eligible for screening. Only HER2 negative (HER2-) patients were eligible for this treatment; HR positive (HR+) patients had to be MP high risk. Treatment included Paclitaxel 80 mg/m2 IV weekly x 12 and Cemiplimab 350 mg and REGN3767 1600 mg both given q3weeks x 4, followed by doxorubicin/cyclophosphamide (AC) every 2 weeks x 4. The control arm was weekly paclitaxel x 12 followed by AC every 2-3 weeks x 4. Cemiplimab/REGN3767 was eligible to graduate in 3 of 10 pre-defined signatures: HER2-, HR-HER2-, and HR+HER2-. The statistical methods for evaluating I-SPY 2 agents has been previously described. To adapt to changing standard of care, we constructed “dynamic controls” comprising ‘best’ alternative therapies using I-SPY 2 and external data and estimated the probability of Cemiplimab/REGN3767 being superior to the dynamic control. Response predictive subtypes (Immune+ vs Immune-) were assessed using pre-treatment gene expression data and the ImPrint signature. Results: 73 HER2- patients (40 HR+ and 33 HR-) received Cemiplimab/REGN3767 treatment. The control group included [357 patients with HER2- tumors (201 HR+ and 156 HR-) enrolled since March 2010. Cemiplimab/REGN3767 graduated in both HR-/HER2- and HR+/HER2- groups; estimated pCR rates (as of June 2022) are summarized in the table. Safety events of note for Cemiplimab/REGN3767 include hypothyroidism 30.8%, adrenal insufficiency (AI) 19.2%, hyperthyroidism 14.1%, pneumonitis 1.3%, and hepatitis 3.8%. All were G1/2 except for 6 (7.7%) G3 AI and 3 (3.8%) G3 colitis. Rash occurred in 62.8%, 9% G3 and 2 pts (2.6%) had pulmonary embolism. X% of adrenal insufficiency cases required replacement therapy. 40 patients (11 HR+ and 29 HR-) in Cemiplimab/REGN3767 were predicted Immune+; 32 (29 HR+ and 3 HR-) were predicted Immune-. In the HR+ group pCR was achieved in 10/11 (91%) patients with Immune+ subtype compared with 8/29 (28%) with Immune- subtype. Additional biomarker analyses are ongoing and will be presented at the meeting. Conclusion: The I-SPY 2 study aims to assess the probability that investigational regimens will be successful in a phase 3 neoadjuvant trial. Dual immune blockade with a LAG-3 inhibitor and anti-PD1 therapy resulted in a high predicted pCR rate both in HR-/HER2- (60%) and HR+/HER2- (37%) disease. The novel Imprint signature identified a group of HR+ patients most likely to benefit from this active regimen. Table 1: Estimated pCR rates Citation Format: Claudine Isaacs, Rita Nanda, Jo Chien, Meghna S. Trivedi, Erica Stringer-Reasor, Christos Vaklavas, Judy C. Boughey, Amy Sanford, Anne Wallace, Amy S. Clark, Alexandra Thomas, Kathy S. Albain, Laura C. Kennedy, Tara B. Sanft, Kevin Kalinsky, Hyo S. Han, Nicole Williams, Mili Arora, Anthony Elias, Carla Falkson, Smita Asare, Ruixiao Lu, Maria Pitsouni, Amy Wilson, Jane Perlmutter, Hope Rugo, Richard Schwab, W. Fraser Symmans, Nola M. Hylton, Laura Van’t Veer, Douglas Yee, Angela DeMichele, Donald Berry, Laura J. Esserman, I-SPY Investigators. Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr GS5-03.
Treatment with inhaled nitric oxide is associated with improved survival in preterm neonates diagnosed with pulmonary hypoplasia
Ellsworth, Kevin, Asay, Garth F., Ellsworth, Marc A., Sangaralingham, Lindsey R. , Colby, Christopher E. , Carey, William A., Clark, Reese H.

Mayo Clinic

Pediatrics | March 1, 2023 | Volume: 142 | Issue: 1_MeetingAbstract | Pages: 148-148

10.1542/peds.142.1ma2.148 Get It

Lateral Epicondylitis
Marigi, Erick M. , Dancy, Malik, Alexander, Andrew , Marigi, Ian , Clark, Julian , Camp, Christopher L. , Okoroha, Kelechi R. , Marigi, Ian M , Camp, Christopher L. , Okoroha, Kelechi R , Marigi, Erick , Alexander, Andrew S , Clark, Clarence Julian , Krych, Aaron J.

Mayo Clinic

JBJS Reviews | February 17, 2023 | Volume: 11 | Issue: 2 | Pages: No page available

10.2106/jbjs.rvw.22.00170 | PMID 36800442 Get It

» Lateral epicondylitis (LE) or tennis elbow is a common cause of elbow pain in the general population, especially women in the fourth and fifth decades of life who participate in repetitive forceful movements involving the wrist and forearm. » The pathogenesis of this overuse injury is believed to start from an overload event leading to a microtear in or near the origin of the extensor carpi radialis brevis that is subsequently prone to additional injury and structural weakness over time. » Treatment of LE often begins with a wide variety of nonoperative modalities including rest, nonsteroidal anti-inflammatory drugs, bracing, and physical therapy. For recalcitrant symptoms, additional nonoperative therapies are implemented; however, there remains a lack of comparative efficacy between these adjunct treatments. » In this article, we examine the available literature regarding nonoperative management of LE and provide supplementary insight into the effectiveness of current modalities.
Comorbidity and Severity in Childhood Apraxia of Speech: A Retrospective Chart Review
Chenausky, Karen , Baas, Becky S. , Stoeckel, Ruth , Brown, Taylor M. , Green, Jordan R. , Runke, Cassandra , Schimmenti, Lisa A. , Clark, Heather M. , Chenausky, Karen V , Baas, Becky, Brown, Taylor , Schimmenti, Lisa, Clark, Heather M , Schimmenti, Lisa A , Stoeckel, Ruth

Mayo Clinic

Journal of Speech, Language, and Hearing Research | February 16, 2023 | Volume: 66 | Issue: 3 | Pages: 791-803

10.1044/2022_jslhr-22-00436 | PMID 36795544 Get It

Purpose: The purpose of this study was to investigate comorbidity prevalence and patterns in childhood apraxia of speech (CAS) and their relationship to severity. Method: In this retroactive cross-sectional study, medical records for 375 children with CAS ( M age = 4;9 [years;months], SD = 2;9) were examined for comorbid conditions. The total number of comorbid conditions and the number of communication-related comorbidities were regressed on CAS severity as rated by speech-language pathologists during diagnosis. The relationship between CAS severity and the presence of four common comorbid conditions was also examined using ordinal or multinomial regressions. Results: Overall, 83 children were classified with mild CAS; 35, with moderate CAS; and 257, with severe CAS. Only one child had no comorbidities. The average number of comorbid conditions was 8.4 ( SD = 3.4), and the average number of communication-related comorbidities was 5.6 ( SD = 2.2). Over 95% of children had comorbid expressive language impairment. Children with comorbid intellectual disability (78.1%), receptive language impairment (72.5%), and nonspeech apraxia (37.3%; including limb, nonspeech oromotor, and oculomotor apraxia) were significantly more likely to have severe CAS than children without these comorbidities. However, children with comorbid autism spectrum disorder (33.6%) were no more likely to have severe CAS than children without autism. Conclusions: Comorbidity appears to be the rule, rather than the exception, for children with CAS. Comorbid intellectual disability, receptive language impairment, and nonspeech apraxia confer additional risk for more severe forms of CAS. Findings are limited by being from a convenience sample of participants but inform future models of comorbidity. Supplemental Material: https://doi.org/10.23641/asha.22096622
Association of Polygenic Score and the involvement of Cholinergic and Glutamatergic Pathways with Lithium Treatment Response in Patients with Bipolar Disorder
Amare, Azmeraw T. , Thalamuthu, Anbupalam , Schubert, Klaus Oliver , Fullerton, Janice M. , Heilbronner, Urs , Hsu, Yi‐Hsiang , Shekhtman, Tatyana , Adli, Mazda , Akula, Nirmala , Akiyama, Kazufumi , Ardau, Raffaella , Aubry, Jean‐Michel , Bhattacharjee, Abesh Kumar, Benabarre, Antoni, Bengesser, Susanne , Birner, Armin , Cervantes, Pablo , Chillotti, Caterina , Cichon, Sven , Cruceanu, Cristiana , Dalkner, Nina , Zompo, Maria Del , Forstner, Andreas J. , Frisén, Louise , Frye, Mark A. , Gard, Sébastien, Fallgatter, Andreas J. , Stegmaier, Sophia, Biere, Silvia, Petrova, Kristiyana, Schuster, Ceylan, Heilbronner, Maria , Kálmán, János , Kohshour, Mojtaba Oraki , Schaupp, Sabrina K. , Senner, Fanny , Vogl, Thomas , Anghelescu, Ion‐George , Arolt, Volker , Dietrich, Detlef E. , Figge, Christian, Jäger, Markus , Juckel, Georg , Reimer, Jens , Schmauß, Max, Konrad, Carsten , Hagen, Martin von, Zimmermann, Jörg, Andlauer, Till F. M. , Bermpohl, Felix , Kraft, Vivien , Gryaznova, Anna, Yildiz, Cüneyt , Kircher, Tilo , Gade, Katrin , Trost, Sarah , Lambert, Martin , Rohenkohl, Anja , Grof, Paul , Kahn, Jean‐Pierre, Kassem, Layla, Kittel‐Schneider, Sarah , Ferensztajn‐Rochowiak, Ewa , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leckband, Susan G. , McCarthy, Michael J. , Mitjans, Marina , Mondimore, Francis M. , Nöthen, Markus M. , O’Donovan, Claire , Pisanu, Claudia , Potash, James B. , Schalling, Martin , Schweizer, Barbara , Severino, Giovanni , Shilling, Paul D. , Shimoda, Kazutaka , Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Maj, Mario , Vieta, Eduard , Veeh, Julia, Witt, Stephanie H. , Zandi, Peter P. , Bauer, Michael , Clark, Scott R. , Amare, Azmeraw , Fullerton, Janice M , Papiol, Sergi , Heilbronner, Urs , Biernacka, Joanna , Marie-Claire, Cynthia , Chen, Hsi-Chung , Cichon, Sven , Cruceanu, Cristiana , Czerski, Piotr , Del Zompo, Maria , Etain, B , Jamain, Stéphane , Forstner, Andreas J , Frye, Mark , Garnham, Julie , Goes, Fernando , Grigoroiu-Serbanescu, Maria , Kalman, Janos , Schulte, Eva , Wiltfang, Jens , Andlauer, Till , Kraft, Vivien , Hauser, Joanna , Kuo, Po-Hsiu , Kittel-Schneider, Sarah , Kusumi, Ichiro , Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Tortorella, Alfonso , McCarthy, Michael , Nöthen, Markus M , Novak, Tomas , Pisanu, Claudia , Reif, Andreas , Reininghaus, Eva , Rouleau, Guy Armand , Schalling, Martin , Schofield, Peter R , Severino, Giovanni , Shimoda, Kazutaka , Squassina, Alessio , Stopkova, Pavla , Turecki, Gustavo , Vieta, E , Witt, Stephanie H , Zandi, Peter P , Alda, Martin , Rietschel, Marcella , McMahon, Francis , Millischer, Vincent , Clark, Scott , Thalamuthu, Anbupalam , Kircher, Tilo T J , Schubert, Klaus Oliver , Mitjans, Marina , Ahmed, Muktar Beshir , Hartmann, Simon , Papiol, Sergi , Degenhardt, Franziska , Tekola‐Ayele, Fasil , Hou, Liping , Arias, Bárbara , Backlund, Lena , Bellivier, Frank , Benabarre, Antoni , Biernacka, Joanna M. , Chen, Hsi‐Chung , Czerski, Piotr M. , Dalkner, Nina , DePaulo, J Raymond , Étain, Bruno , Jamain, Stéphane , Falkai, Peter , Grigoroiu‐Serbânescu, Maria , Ethofer, Thomas , Adorjan, Kristina , Budde, Monika , Reich‐Erkelenz, Daniela , Schulte, Eva C. , Dannlowski, Udo , Lang, Fabian U. , Spitzer, Carsten , Schmitt, Andrea , Wiltfang, Jens , Zimmermann, Jörg , Fischer, André , Matura, Silke , Gryaznova, Anna, Falkenberg, Irina , Schmidt, Julia Katharina , Koch, Marius, Haussleiter, Ida Sibylle , Hashimoto, Ryota , Herms, Stefan , Hoffmann, Per , Jiménez, Esther , Kuo, Po‐Hsiu , Kato, Tadafumi , Kelsoe, John R , König, Barbara , Leboyer, Marion , Tortorella, Alfonso , Manchia, Mirko , Martinsson, Lina , McElroy, Susan L. , Colom, Francesc , Monteleone, Palmiero , Nievergelt, Caroline M , Novák, Tomáš , Ozaki, Norio , Pfennig, Andrea , Reif, Andreas , Rybakowski, Janusz K , Schofield, Peter R. , Squassina, Alessio , Stopková, Pavla , Turecki, Gustavo , Wright, Adam, Mitchell, Philip B , Alda, Martin , McMahon, Francis J. , Schulze, Thomas , Baune, Bernhard

Mayo Clinic

No container title available | February 14, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2580252/v1 | PMID 36824922 Get It

Abstract Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consistently effective, with only 30% of patients showing a favorable response to treatment. To provide personalized treatment options for bipolar patients, it is essential to identify prediction biomarkers such as polygenic scores. In this study, we developed a polygenic score for lithium treatment response (Li+PGS) in patients with BD. To gain further insights into lithium's possible molecular mechanism of action, we performed a genome-wide gene-based analysis. Using polygenic score modeling, via methods incorporating Bayesian regression and continuous shrinkage priors, Li+PGS was developed in the International Consortium of Lithium Genetics cohort (ConLi+Gen: N=2,367) and replicated in the combined PsyCourse (N=89) and BipoLife (N=102) studies. The associations of Li+PGS and lithium treatment response — defined in a continuous ALDA scale and a categorical outcome (good response vs. poor response) were tested using regression models, each adjusted for the covariates: age, sex, and the first four genetic principal components. Statistical significance was determined at P<����������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
Rate Modulation Abilities in Acquired Motor Speech Disorders
Utianski, Rene L. , Duffy, Joseph R. , Martin, Peter R. , Clark, Heather M. , Stierwalt, Julie A. G., Botha, Hugo , Ali, Farwa , Whitwell, Jennifer L. , Josephs, Keith A. , Utianski, Rene L , Botha, Hugo , Clark, Heather M , Duffy, Joseph R , Whitwell, Jennifer L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | February 13, 2023 | Volume: 66 | Issue: 8S | Pages: 3194-3205

10.1044/2022_jslhr-22-00286 | PMID 36780318 Get It

Purpose: The purpose of this study was to describe, compare, and understand speech modulation capabilities of patients with varying motor speech disorders (MSDs) in a paradigm in which patients made highly cued attempts to speak faster or slower. Method: Twenty-nine patients, 12 with apraxia of speech (AOS; four phonetic and eight prosodic subtype), eight with dysarthria (six hypokinetic and two spastic subtype), and nine patients without any neurogenic MSD completed a standard motor speech evaluation where they were asked to repeat words and sentences, which served as their “natural” speaking rate. They were then asked to repeat lower complexity (counting 1–5; repeating “cat” and “catnip” 3 times each) and higher complexity stimuli (repeating “catastrophe” and “stethoscope” 3 times each and “My physician wrote out a prescription” once) as fast/slow as possible. Word durations and interword intervals were measured. Linear mixed-effects models were used to assess differences related to MSD subtype and stimuli complexity on bidirectional rate modulation capacity as indexed by word duration and interword interval. Articulatory accuracy was also judged and compared. Results: Patients with prosodic AOS demonstrated a reduced ability to go faster; while they performed similarly to patients with spastic dysarthria when counting, patients with spastic dysarthria were able to increase rate similar to controls during sentence repetition; patients with prosodic AOS could not and made increased articulatory errors attempting to increase rate. AOS patients made more articulatory errors relative to other groups, regardless of condition; however, their percentage of errors reduced with an intentionally slowed speaking rate. Conclusions: The findings suggest comparative rate modulation abilities in conjunction with their impact on articulatory accuracy may support differential diagnosis between healthy and abnormal speech and among subtypes of MSDs (i.e., type of dysarthria or AOS). Findings need to be validated in a larger, more representative cohort encompassing several types of MSDs. Supplemental Material: https://doi.org/10.23641/asha.22044632
Assessing Patients and Care Partner Ratings of Communication-Related Participation Restrictions: Insights From Degenerative Disease
Utianski, Rene L. , Martin, Peter R. , Duffy, Joseph R. , Clark, Heather M. , Stierwalt, Julie A. G., Botha, Hugo , Ali, Farwa , Whitwell, Jennifer L. , Josephs, Keith A. , Utianski, Rene L , Botha, Hugo , Clark, Heather M , Duffy, Joseph R , Whitwell, Jennifer L.

Mayo Clinic

American Journal of Speech-Language Pathology | February 9, 2023 | Volume: 32 | Issue: 4S | Pages: 1793-1805

10.1044/2022_ajslp-22-00140 | PMID 36758199 Get It

Purpose: Prior studies have shown that communication-related participation restrictions in patients with degenerative disease do not always match clinician judgment or objective indices of symptom severity. Although there is a growing body of literature documenting that discrepancies between patients with dementia and their care partners' perception of participation restrictions exist, it is not known how care partner perceptions of communication participation restrictions specifically match or diverge from the patients' experiences, which may inform the use of care partner proxy in the context of degenerative diseases. Method: Thirty-eight patients with progressive neurologic conditions (progressive supranuclear palsy, corticobasal syndrome, and primary progressive aphasia or apraxia of speech) and, in most instances, focal cognitive-communication disorders were included. The patients and their accompanying care partners independently completed the Communicative Participation Item Bank, short form, a 10-question survey about communication participation restrictions in different contexts. Care partners were instructed to complete the form with their perception of the patient's experience. The difference between patient and care partner total scores were calculated and analyzed relative to clinical and demographic variables of interest. Results: Care partner ratings modestly tracked with patient experience and objective indices of symptom severity but did not exactly match patient ratings. The presence of aphasia increased, but did not fully account for, the likelihood of a discrepancy between care partner and patient ratings. Conclusion: Although careful consideration should be given prior to using care-partner report as a proxy for patient experience, it is worthwhile to include care partner ratings as a means of supporting conversations about differing perceptions, guiding joint intervention planning, and monitoring care-partner perceptions of change along with the implementation of supported conversation strategies.
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
Vollstedt, Eva‐Juliane , Schaake, Susen , Lohmann, Katja , Lesage, Suzanne , Tesson, Christelle , Wurster, Isabel , Hentati, F., Marder, Karen, Waters, Cheryl , Fahn, Stanley, Brüggemann, Norbert , Tolosa, Eduardo , Garrido, Alícia , Annesi, Grazia , Bozi, Maria , Ferreira, Joaquim J. , Guedes, Leonor Correia , Petrucci, Simona , Clark, Lorraine N. , Abramycheva, Natalya, Menéndez‐González, Manuel , Maestre, S. Jesús, Gómez‐Garre, Pilar , Mir, Pablo , Ran, Caroline , Kuo, Ming‐Che , Ross, Owen A. , Williams‐Gray, Caroline H. , Camacho, Marta , Cornejo‐Olivas, Mario , Torres-Ramírez, Luis , Wu, Yih‐Ru , Morgadinho, Ana , Berg, Daniela , Kuhlenbäumer, Gregor , Kühn, Andrea A. , Borngräber, Friederike , Michele, Giuseppe De , Rosa, Anna De , Zimprich, Alexander , Puschmann, Andreas , Mellick, George D. , Chase, Bruce A. , Markopoulou, Katerina , Satake, Wataru , Rossi, Malco , Lynch, Timothy , Olszewska, Diana A. , Lim, Shen‐Yang , Ahmad‐Annuar, Azlina , Tan, Ai Huey , Hanağası, Haşmet , Koziorowski, Dariusz , Ertan, Sibel , Genç, Gençer , Saunders‐Pullman, Rachel , Warrenburg, Bart van de, Bressman, Susan , Toft, Mathias , Appel‐Cresswell, Silke , Boon, Agnita J.W. , Krüger, Rejko , Sammler, Esther , Tumas, Vítor , Zhang, Baorong , Garraux, Gaëtan , Kim, Yun Joong , Winkelmann, Juliane , Sue, Carolyn M. , Tan, Eng‐King , Kostić, Vladimir , Arkadir, David , Martikainen, Mika H. , Brighina, Laura , Suchowersky, Oksana , Rieß, Olaf , Das, Parimal, Mollenhauer, Brit , Gatto, Emilia , Petersen, Maria Skaalum , Aasly, Jan , Aasly, Anna, Farrer, Matthew J. , Brockmann, Kathrin , Klein, Christine , Group, the MJFF Global Genetic Parkinson's Disease Study, Bardien, Soraya , Barrett, Matthew J. , Januário, Cristina , Sousa, Mário , Soto‐Beasley, Alexandra I. , May, Patrick , Mirelman, Anat , Brüggemann, Norbert , Borsche, Max , Tolosa, Eduardo , Ferreira, Joaquim J , Alvarez, Victoria , Mir, Pablo , Kuo, Ming-Che , Ross, Owen A , Nishioka, Kenya , Williams-Gray, Caroline H , Camacho, Marta , Cornejo-Olivas, Mario , Wu, Yih-Ru , Termsarasab, Pichet , Borngräber, Friederike , Zimprich, Alexander , Gambardella, Stefano , Chase, Bruce , Olszewska, Diana A , Tan, Ai Huey , Barkhuizen, Melinda , Appel-Cresswell, Silke , Skorvanek, Matej , Sammler, Esther M , Zhang, Baorong , Chung, Sun Ju , Puschmann, Andreas , Januário, Cristina , Klein, Christine , Bardien, Soraya , Toft, Mathias , Koziorowski, Dariusz , May, Patrick , Beasley, Alexandra I , Barrett, Matthew J , Sue, Carolyn M , Kühn, Andrea A , Padmanabhan, Shalini , Brice, Alexis , Vidailhet, Marie , Giladi, Nir , Kasten, Meike , Borsche, Max , Foroud, Tatiana , Gagliardi, Monica , Stefanis, Leonidas , Avenali, Micol , Fedotova, E. Yu. , Álvarez, Victoria , Belin, Andrea Carmine , Lin, Chin‐Hsien , Crosiers, David , Wszołek, Zbigniew K. , Jankovic, Joseph J. , Funayama, Manabu , Clarimón, Jordi , Lee‐Chen, Guey‐Jen , Pulkes, Teeratorn , Dorszewska, Jolanta , Carr, Jonathan , Ferese, Rosangela , Toda, Tatsushi , Merello, Marcelo , Al-Mubarak, Bashayer R , Aguiar, Patrícia de Carvalho , Pimentel, Márcia Mattos Gonçalves , Warrenburg, Bart P.C. van de , Lang, Anthony E. , Damásio, Joana , Klivènyi, Péter , Borges, Vanderci , Hertz, Jens Michael , Spitz, Mariana , Hattori, Nobutaka , Wu, Ruey‐Meei , Illarioshkin, Sergey Nikolaevich , Valente, Enza Maria , Alcalay, Roy N. , Thaler, Avner , Corvol, Jean‐Christophe , Group, the MJFF Global Genetic Parkinson's Disease Study

Mayo Clinic

Movement Disorders | January 24, 2023 | Volume: 38 | Issue: 2 | Pages: 286-303

10.1002/mds.29288 | PMID 36692014 Get It

AbstractBackgroundAs gene‐targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial‐ready cohorts is limited.ObjectiveThe objectives are to (1) establish an international cohort of affected and unaffected individuals with PD‐linked variants; (2) provide harmonized and quality‐controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD.MethodsWe conducted a worldwide, systematic online survey to collect individual‐level data on individuals with PD‐linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ‐1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype–phenotype relationships were analyzed.ResultsWe collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ‐1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published.ConclusionsWithin the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD‐linked variants; (2) provide harmonized and quality‐controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene‐targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
TMEM161B regulates cerebral cortical gyration, Sonic Hedgehog signaling, and ciliary structure in the developing central nervous system
Akula, Shyam K. , Marciano, Jack H. , Lim, Youngshin , Exposito-Alonso, David , Hylton, Norma K. , Hwang, Grace H. , Neil, Jennifer E., Dominado, Nicole , Bunton-Stasyshyn, Rosie , Song, Janet , Talukdar, Maya , Schmid, Aloisia, Teboul, Lydia , Mo, Alisa , Finander, Benjamin , Beck, Samantha G., Yeh, Rebecca C., Otani, Aoi, Qian, Xuyu , DeGennaro, Ellen M. , Alkuraya, Fowzan S. , Maddirevula, Sateesh , Cascino, Gregory D. , Network, Undiagnosed Diseases, Burrage, Lindsay C. , Rosenfield, Jill A., Ketkar, Shamika , Clark, Gary, Bacino, Carlos A. , Lewis, Richard A. , Segal, Rosalind A. , Bazán, J. Fernando , Smith, K. A. , Golden, Jeffrey A. , Cho, Ginam , Walsh, Christopher A. , Alejandro, Mercedes E., Ashley, Euan A. , Baker, Eva H. , Balasubramanyam, Ashok , Barseghyan, Hayk , Batzli, Gabriel F., Bernstein, Jonathan A. , Bican, Anna, Bick, David , Birch, Camille L., Boone, Braden, Bostwick, Bret L. , Briere, Lauren C. , Brokamp, Elly , Brush, Matthew , Chen, Shan , Coakley, Terra R., Cobban, Laurel A., Colley, Heather A., Cooper, Cynthia M. , Craigen, William J., D’Souza, Precilla , Davids, Mariska, Davidson, Jean M. , Dayal, Jyoti G. , Dell’Angelica, Esteban C., Dhar, Shweta U. , Dipple, Katrina M. , Dorrani, Naghmeh, Dorset, Daniel C., Douglas, Jessica, Draper, David D., Dries, Annika M., Eckstein, David J. , Emrick, Lisa , Eng, Christine M. , Enns, Gregory M. , Eskin, Ascia , Esteves, Cecilia, Estwick, Tyra, Fernández, Liliana, Fogel, Brent L. , Friedman, Noah D., Gahl, William A. , Godfrey, Rena A., Goldstein, David B. , Gould, Sarah E., Groden, Catherine, Hamid, Rizwan , Hanchard, Neil A. , High, Frances A. , Hom, Jason , Howerton, Ellen M. , Jamal, Fariha , Jiang, Yong‐hui , Johnston, Jean M., Karaviti, Lefkothea , Kelley, Emily G., Koeller, David M. , Kohane, Isaac S. , Kohler, Jennefer N., Korrick, Susan , Kozuira, Mary, Krasnewich, Donna M., Krier, Joel B. , Lau, C. Christopher, Lazar, Jozef, LeBlanc, Kimberly , Lee, Brendan , Lee, Hane , Lewis, Richard A., Loscalzo, Joseph, Maas, Richard L., MacRae, Calum A. , Maduro, Valerie V. , Majcherska, Marta M., Malicdan, May Christine V. , Mamounas, Laura A., Manolio, Teri A. , Markello, Thomas C. , Martín, Martín G., Marwaha, Shruti , May, Thomas , McConkie‐Rosell, Allyn , McCormack, Colleen E., McCray, Alexa T. , Merker, Jason D. , Moretti, Paolo , Morimoto, Marie , Murdock, David R. , Muzny, Donna M., Nehrebecky, Michele, Nelson, Stan F., Newberry, J. Scott, Newman, John H. , Nicholas, Sarah K. , Novacic, Donna, Orengo, James P. , Pallais, J. Carl , Palmer, Christina G.S. , Papp, Jeanette C. , Parker, Neil H., Peña, Loren D.M. , Phillips, John A., Potocki, Lorraine , Pusey, Barbara N., Renteria, Genecee, Rives, Lynette, Robertson, Amy K., Rodan, Lance H. , Sampson, Jacinda B. , Samson, Susan L. , Schoch, Kelly, Shakachite, Lisa, Sharma, Prashant , Shashi, Vandana , Signer, Rebecca , Silverman, Edwin K. , Smith, Kevin S., Spillmann, Rebecca C. , Stoler, Joan M. , Sullivan, Jennifer A. , Tan, Queenie K.‐G., Tan, Wen-Haan, Toro, Camilo , Tran, Alyssa A., Urv, Tiina K. , Vogel, Tiphanie P. , Waggott, Daryl, Wahl, Colleen E., Walker, Melissa , Walley, Nicole M., Wan, Jijun , Ward, Patricia A., Westerfield, Monte, Wise, Anastasia L., Wolfe, Lynne A. , Yang, Yaping , Yoon, Amanda J., Yu, Guoyun, Zastrow, Diane B. , Zhao, Chunli , Zheng, Allison, Bunton-Stasyshyn, Rosie K , DeGennaro, Ellen M , Cascino, Gregory D , Giannini, Caterina , Burrage, Lindsay C , Rosenfield, Jill A , Bacino, Carlos , Lewis, Richard A , Segal, Rosalind A , Bazan, J Fernando , Smith, Kelly A , Golden, Jeffrey A , Cho, Ginam , Walsh, Christopher A , Alkuraya, Fowzan S , Akula, Shyam K , Shin, Taehwan , Giannini, Caterina , Network, Undiagnosed Diseases, Adams, David R. , Aday, Aaron W. , Allard, Patrick , Azamian, Mahshid S. , Beggs, Alan H. , Behnam, Babak , Bellen, Hugo J. , Berry, Gerard T. , Bonner, Devon E. , Brown, Donna M. , Burke, Elizabeth A. , Butte, Manish J. , Cogan, Joy D. , Cope, Heidi , D’Souza, Precilla , Douine, Emilie D. , Ferreira, Carlos R , Fieg, Elizabeth L. , Fisher, Paul Graham , Goldman, Alica M. , Gourdine, Jean-Philippe F. , Gropman, Andrea L , Haendel, Melissa , Holm, Ingrid A. , Huang, Yong , Jones, Angela , Kyle, Jennifer E , Lalani, Seema R , Levy, Shawn , Lewis, Richard A., Loo, Sandra K. , Macnamara, Ellen F. , Marom, Ronit , Martínez-Agosto, Julián A. , May, Thomas, Metz, Thomas , Might, Matthew , Mochida, Ganeshwaran H. , Mulvihill, John Joseph , Murphy, Jennifer L. , Muzny, Donna M. , Orange, Jordan S. , Phillips, John A., Posey, Jennifer E , Postlethwait, John H. , Reuter, Chloe M. , Rosenfeld, Jill A. , Scott, Daryl A , Sinsheimer, Janet S. , Stong, Nicholas , Sweetser, David A , Tifft, Cynthia , Vilain, Eric J. N. , Walley, Nicole M., Wangler, Michael F , Waters, Katrina M. , Webb‐Robertson, Bobbie‐Jo , Wheeler, Matthew T , Worthey, Elizabeth A. , Yamamoto, Shinya , Yang, John Jeongseok

Mayo Clinic

Proceedings of the National Academy of Sciences | January 20, 2023 | Volume: 120 | Issue: 4 | Pages: No page available

10.1073/pnas.2209964120 | PMID 36669111 Get It

Sonic hedgehog signaling regulates processes of embryonic development across multiple tissues, yet factors regulating context-specific Shh signaling remain poorly understood. Exome sequencing of families with polymicrogyria (disordered cortical folding) revealed multiple individuals with biallelic deleterious variants in TMEM161B , which encodes a multi-pass transmembrane protein of unknown function. Tmem161b null mice demonstrated holoprosencephaly, craniofacial midline defects, eye defects, and spinal cord patterning changes consistent with impaired Shh signaling, but were without limb defects, suggesting a CNS-specific role of Tmem161b. Tmem161b depletion impaired the response to Smoothened activation in vitro and disrupted cortical histogenesis in vivo in both mouse and ferret models, including leading to abnormal gyration in the ferret model. Tmem161b localizes non-exclusively to the primary cilium, and scanning electron microscopy revealed shortened, dysmorphic, and ballooned ventricular zone cilia in the Tmem161b null mouse, suggesting that the Shh-related phenotypes may reflect ciliary dysfunction. Our data identify TMEM161B as a regulator of cerebral cortical gyration, as involved in primary ciliary structure, as a regulator of Shh signaling, and further implicate Shh signaling in human gyral development.